After a big 2nd half of 2016 and some strength in early 2017, Canadian LPs were under heavy pressure from April through June following a glut of supply (new publicly-trading LPs, capital raises) and a marked increase in the pace of licensing by Health Canada. The market also priced in some uncertainty surrounding distribution and how it will impact the rollout of legal cannabis sales next year.

With just another trading session to go, it looks like the LPs will have their first positive full month since February. My proprietary index rose 4.9% in January and 10.5% in February but declined 5.9% in March, 4.4% in April, 12.4% in May and 11.2% in June before rebounding 14.1% through mid-day trading today, leaving the index still down 7.5% YTD. 17 of the 19 LPs in the index have rallied this month:

Three names have increased over 25%, with Cronos Group (TSXV: MJN) (OTC: PRMCF), Invictus MD Strategies (TSXV: IMH) (OTC: ITIVF) and CanniMed Therapeutics (TSX: CMED) (OTC: CMMDF) showing leadership this month. Cronos Group is the best performing LP YTD, up 49.3%. CanniMed has recovered most of its losses in 2017, down 3.6%, but it continues to trade below its $12 IPO price from late 2016.

Aurora Cannabis (TSX: ACB) (OTC: ACBFF), Emblem (TSXV: EMC) (OTC: EMMBF), Harvest One (TSXV: HVST) (OTC: HRVOF) and Aphria (TSX: APH) (OTC: APHQF) are each up 20-25%. Aurora, which graduated to the TSX just this week, is up 17% in 2017. Aphria, which is the second best performer in 2017, is up 29.6% after reporting a strong FY17-Q4 earlier this month. Emblem has rallied sharply but is still down 47.9% YTD. Harvest One too has begun to rebound after being pressured following its debut in May.

The LPs up more than 10% so far in July include Canopy Growth (TSX: WEED) (OTC: TWMJF), Hydropothecary (TSXV: THCX) (OTC: HYYDF), Maricann Group (CSE: MARI) (OTC: MRRCF), Organigram (TSXV: OGI) (OTC: OGRMF) and Emerald Health (TSXV: EMH) (OTC: EMHTF). Canopy has performed well since announcing a $25mm private placement at $8.05 and is now up 0.9% in 2017. The company will be reporting its FY18-Q1 results by mid-August. Maricann has caught traders’ attention as a play on the German medical cannabis market.

Newstrike (TSXV: HIP) (OTC: NWRKF), Beleave (CSE: BE) (OTC: BLEVF), WeedMD (TSXV: WMD) (OTC: WDDMF), ABcann Global (TSXV: ABCN) (OTC: ABCCF) and Supreme Pharma (TSXV: FIRE) (OTC: SPRWF) are all up less than 10%. ABcann was able to finalize its sale of stock at a substantial premium as part of a deal with Cannabis Wheaton (TSXV: CBW) (OTC: KWFLF) earlier this month. Supreme announced earlier this month that it can now sell cannabis after having received its cultivation license 15 months earlier. Insiders have been buying shares.

MedReleaf (TSX: LEAF) (OTC: MEDFF) and THC BioMed (CSE: THC) (OTC: THCBF) are the only two LPs in the red. THC BioMed, which has been unable to raises substantial capital like its peers, is the worst performing LP YTD, down almost 60%. MedReleaf continues to trade about 15% below its recent IPO price of $9.50. The company will report its FY18-Q1 results on 8/14.

In addition to the 19 LPs mentioned, TerrAscend (CSE: TER) began trading as an LP earlier this month after receiving its Health Canada cultivation license and will join the index next week. DOJA Cannabis expects to begin trading next week on the CSE with the symbol “DOJA”, and CannTrust and The Green Organic Dutchman are in the process of going public later this year. To stay on top of the Canadian LP sector, readers can visit our dedicated resource page.

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Exclusive article by Alan Brochstein, CFA Facebook | LinkedIn | Email Based in Houston, Alan leverages his experience as founder of online communities 420 Investor , the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures , he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha , where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter